PRC
ARNA

Pearl River Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Pearl River Capital’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-432
Closed -$17K – 915
2018
Q4 		$17K Buy
+432
New +$17K 0.08% 363

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Pearl River Capital's ARNA Position: Q1 2019 in Review

Pearl River Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2019, closing a stake of 432 shares — an estimated $17K sold.

Pearl River Capital first reported a position in ARNA in Q4 2018 and held it in 1 quarter. The position peaked at $17K in Q4 2018. 184 funds tracked by Wall St. Rank hold ARNA as of Q1 2019.

  • Pearl River Capital reported no remaining Arena Pharmaceuticals Inc position as of Q1 2019 after selling out during the quarter.
  • Pearl River Capital sold 432 Arena Pharmaceuticals Inc shares in Q1 2019, an estimated $17K.
  • Pearl River Capital first reported a position in Arena Pharmaceuticals Inc in Q4 2018 and held it in 1 quarter.
  • Pearl River Capital's Arena Pharmaceuticals Inc position peaked at $17K in Q4 2018.
  • 184 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.